Financial Health Assessment: COMCARDE LIMITED (trading as BR-DGE)

Patient profile: Scottish private limited company (SC454090), incorporated July 2013, based in Edinburgh. Operates in payment orchestration software (SIC 62012/62090). Venture-backed scale-up, majority-controlled by institutional investors. Status: Active, not in liquidation. Latest accounts made up to 31 December 2025, filed on time, with a clean audit opinion.

1. Financial Health Score: C (Guarded — Stable but Liquidity-Critical)

Why a C? This is a company with a strong athletic heart (growth) and a dangerously thin pulse (cash). It would score a D on liquidity alone were it not for the £10m post-balance-sheet injection, which functions as a transfusion administered just after the year-end blood test. The trajectory is improving, but the patient is not yet self-sustaining.

2. Key Vital Signs

Supporting observations: - Share capital is only £41. Essentially all equity value sits in share premium — meaning the company's net worth is investor capital, not accumulated profit. The profit and loss reserve is almost certainly deeply negative. - Asset composition is non-cash. With £26.3m of assets and £42.8k of cash, the balance sheet is dominated by capitalised development costs, debtors, or deposits. This is normal for a capitalising software business but raises impairment sensitivity. - No dividends paid and none recommended — clinically appropriate for a growth-stage patient; cash is being reinvested, not extracted. - Filing health is good. Accounts and confirmation statement are both current, with no overdue filings and no penalties. - Governance pulse shows arrhythmia. Two directors (including the Chairman, Xxxxxx Xxxxxxxxname shown to subscribers) resigned in April and June 2026, with two new directors appointed in the same window. Board refresh is common post-funding, but the timing warrants monitoring.

Data caveat: In the filed figures, reported net assets do not reconcile precisely to total assets minus total liabilities in several years, and shareholders' funds diverge from net assets in FY2024 and FY2025. Treat individual line items as directional rather than exact, and verify against the full statutory accounts before relying on them for decision-making. The income statement detail was not available in the extracted text, so burn rate cannot be calculated precisely.

3. Diagnosis

Primary condition: Growth-stage cash starvation, funded by equity rather than operations.

The company is exhibiting the classic symptoms of a high-burn scale-up:

1. Strong systemic growth, weak internal cash generation. Total assets have compounded at roughly 34% a year since 2018, and management reports ARR growth of 375% with tier-1 enterprise contracts going live. The top line is healthy. But the company is not yet converting that growth into cash — it is consuming capital to build it.

2. An acute solvency episode in FY2024. Negative net assets (–£2.57m) and negative shareholders' funds (–£13.47m) represent technical balance sheet insolvency. The company was, on paper, worth less than nothing. This was resolved in FY2025 by a substantial equity injection — equity is now strongly positive at £30.39m. This is the financial equivalent of a patient pulled back from the brink by emergency intervention.

3. A thready pulse at the year-end date. Cash of £42,809 against £9.97m of liabilities is the single most alarming reading in this assessment. For a company of this scale, that represents days — not months — of operating liquidity. The £10m raised after the year-end is what keeps the patient ambulatory, and the auditor's going-concern conclusion (no material uncertainty) rests materially on that post-year-end funding.

4. Chronic dependence on external capital. The business model is a ventilator patient: it breathes because investors keep pumping. Concentrated ownership (Highland & Universal Investments >75% of shares and votes, Monarch Technology Investments 50–75%, plus a 25–50% individual voting interest) means the lifeline exists — but it also means the company's survival is a function of shareholder appetite, not market performance alone.

5. The risk factors management itself identifies are real and material: macro volatility affecting geographic expansion, cybersecurity exposure, regulatory complexity in payments, and AI-driven competitive disruption. For a payments orchestration platform holding SOC2 Type 2 and PCI 4.0 accreditations, security and compliance failures would be systemic events, not inconveniences.

What is not wrong: There are no signs of distress behaviours — no overdue filings, no liquidation or administration markers, no evidence of creditor pressure. The audit opinion is unqualified, and the auditor explicitly found no material going-concern uncertainty. That is a meaningful clean bill of health on governance and reporting integrity.

4. Prognosis

Short term (12 months): Guarded positive. The £10m raise provides a working runway, and contracted enterprise volumes flowing into 2026 support the revenue trajectory. The stated ambition to more than triple transaction volumes in 2026 is achievable but ambitious; execution risk is concentrated in a small number of large enterprise relationships.

Medium term (2–3 years): Binary. Two paths diverge: - Recovery path: ARR converts to gross profit at scale, burn multiple improves, and the company reaches cash-flow breakeven before the current funding is exhausted. This is the outcome the growth metrics point toward. - Relapse path: Growth disappoints, the next round is a down round or fails to materialise, and the thin cash buffer forces emergency measures — cost restructuring, asset sales, or worse. The FY2024 negative-equity episode shows how quickly the balance sheet can deteriorate.

Key prognostic indicators to watch: net revenue retention, gross margin on transaction volume, burn multiple (net burn ÷ net new ARR), cash runway in months, and the timing of the next funding event relative to cash exhaustion.

5. Recommendations

Immediate (0–3 months) 1. Install a 13-week rolling cash flow forecast and an 18-month runway model. This is the ECG. Right now the organisation is managing growth without a continuous liquidity readout, and the year-end cash position suggests visibility is limited. 2. Confirm the composition of the £26.3m asset base. Identify how much is capitalised development, how much is receivables, and how much is genuinely recoverable. Any intangible balance requires impairment testing, and a write-down would hit equity directly. 3. Model the post-year-end £10m against a realistic burn rate and publish a formal runway statement to the board. If runway is under 12 months, that is a board-level red flag requiring immediate action.

Near term (3–12 months) 4. Diversify the funding arteries. Reduce single-channel dependence on equity rounds. Consider venture debt, receivables or revenue-based financing, and — given the explicit R&D programme described in the directors' report — confirm whether R&D tax credit claims are being maximised, as these can be a meaningful cash inflow for loss-making, R&D-intensive companies. 5. Improve cash conversion. Move enterprise customers to annual prepayment or upfront billing where possible, tighten debtor collection, and review take-rate economics per transaction. Growth that doesn't convert to cash is growth on credit. 6. Adopt a formal KPI dashboard for stakeholders. The strategic report lists many metrics qualitatively; publish quantified ARR, net revenue retention, gross margin, burn multiple, and Rule of 40 performance. Investors and lenders will price the next round on these, not on narrative. 7. Stabilise governance. The recent chairman transition and dual director changes should be completed with clear succession documentation and independent oversight. Board churn during a funding cycle is a governance risk factor.

Structural (ongoing) 8. Build a cost-flex plan. Identify the 15–20% of spend that can be paused within 30 days without damaging the core platform. This is the emergency protocol — best written when healthy, not during a crisis. 9. Scenario-plan a down round. Model the cap table and cash position under a 30% lower valuation and a 6-month funding delay. Know in advance which levers you would pull. 10. Maintain the compliance discipline. Filing timeliness and audit cleanliness are genuine strengths here — protect them. Late filing penalties and audit qualifications would compound any future funding difficulty.

Names of the people mentioned are shown to subscribers. See subscription